CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	3 Months Ended
	Jul. 02, 2016	Jun. 27, 2015
Cash Flows from Operating Activities:
Net loss	$ (10,346)	$ (267)
Non-cash items:
Depreciation and amortization	22,544	22,255
Asset impairments	1,766	0
Stock compensation expense	1,840	3,164
Unrealized gain from hedging activities	(907)	(186)
Provision for losses on accounts receivable and inventory	2,571	1,742
Other non-cash operating activities	257	271
Change in operating assets and liabilities:
Change in accounts receivable, net	8,239	6,524
Change in inventories	(3,721)	(2,410)
Change in prepaid income taxes	(932)	(369)
Change in other assets and other liabilities	1,126	3,699
Change in accounts payable and accrued expenses	8,258	(25,173)
Net cash provided by operating activities	30,695	9,250
Cash Flows from Investing Activities:
Capital expenditures	(22,479)	(24,246)
Proceeds from sale of property, plant and equipment	87	116
Other acquisitions and investments	0	(3,000)
Net cash used in investing activities	(22,392)	(27,130)
Cash Flows from Financing Activities:
Payments on long-term real estate mortgage	0	(276)
Net (decrease) increase in short-term loans	(1,261)	4,380
Repayment of term loan borrowings	(7,114)	0
Proceeds from employee stock purchase plan	1,980	2,263
Proceeds from exercise of stock options	1,409	2,893
Share repurchases	0	(39,032)
Net cash used in financing activities	(4,986)	(29,772)
Effect of exchange rates on cash and cash equivalents	(192)	(806)
Net Change in Cash and Cash Equivalents	3,125	(48,458)
Cash and Cash Equivalents at Beginning of Period	115,123	160,662
Cash and Cash Equivalents at End of Period	118,248	112,204
Supplemental Disclosures of Cash Flow Information:
Interest paid	2,072	2,068
Income taxes paid	1,541	1,625
Transfers from inventory to fixed assets for placement of Haemonetics equipment	$ 1,764	$ 2,925